Blood pool contrast agents for cardiovascular MR imaging.
The distribution and elimination of contrast agents is mainly determined by their size. First-pass perfusion with the use of blood pool contrast agents (BPCAs) and/or rapid clearance blood-pool-like contrast agents may allow quantitative myocardial perfusion evaluation in patients. This requires contrast bolus injection with a very fast injection speed. A major profit from BPCAs is expected for magnetic resonance angiography (MRA). The persistent signal-enhancing effects of BPCAs allow for a longer acquisition time window, which may be used to increase both the signal-to-noise ratio and/or image resolution. This is of paramount importance for coronary imaging, in which high-resolution imaging is desired. Moreover, the improved acquisition time window can be used to make multiple scans after one contrast injection. The role of ultrasmall paramagnetic iron oxide particles (USPIOs) for MRA is not clear yet, as they are limited by T2* effects at higher doses. Several safety aspects have to be taken into account before BPCAs are applied in humans, for whom toxicity caused by the injection speed is a concern.
Kroft
L J
LJ
Department of Radiology, C2-S, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
de Roos
A
A
D002318:Cardiovascular Diseases / Q000175:diagnosis*; D003287:Contrast Media / Q000494:pharmacology; D003911:Dextrans; D052203:Ferrosoferric Oxide; D005682:Gadolinium; D006801:Humans; D007501:Iron / Q000494:pharmacology; D046911:Macromolecular Substances; D018810:Magnetic Resonance Angiography; D058185:Magnetite Nanoparticles; D009942:Organometallic Compounds / Q000494:pharmacology; D010087:Oxides / Q000494:pharmacology
D003287:Contrast Media; D003911:Dextrans; D046911:Macromolecular Substances; D058185:Magnetite Nanoparticles; D009942:Organometallic Compounds; D010087:Oxides; C097921:ferumoxtran-10; D005682:Gadolinium; D007501:Iron; D052203:Ferrosoferric Oxide; C109932:gadofosveset trisodium